Naveen Darakshan
Internal Medicine · Ocoee, FLNPI 1184622789
Payments from drug & device makers
Across 159 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$585
- Sanofi-aventis U.S. LLC$487
- Lilly USA, LLC$448
- Novo Nordisk$318
- GSK$280
- Abbott$202
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,28298%
- Education$40%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $585 |
| Sanofi-aventis U.S. LLC | 20 | $487 |
| Lilly USA, LLC | 23 | $448 |
| Novo Nordisk | 12 | $318 |
| GSK | 14 | $280 |
| Abbott | 10 | $202 |
| Boehringer Ingelheim | 8 | $168 |
| Pfizer | 9 | $167 |
| Amgen | 8 | $144 |
| Exact Sciences | 6 | $139 |
| Amarin Pharma, Inc. | 4 | $73 |
| Corcept Therapeutics | 3 | $66 |
| Mannkind Corporation | 1 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| AbbVie(2 entities) | 2 | $38 |
| Johnson & Johnson | 2 | $34 |
| Novartis | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- SOLIQUA 100/33$125
- Ozempic$120
How this compares
$3,346 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $34,499 |
| FarxigaDapagliflozin Propanediol | 28 | $34,222 |
| JanuviaSitagliptin Phosphate | 23 | $30,490 |
| JardianceEmpagliflozin | 12 | $18,180 |
| RybelsusSemaglutide | 12 | $11,773 |
| LinzessLinaclotide | 13 | $10,998 |
| Atorvastatin Calcium | 121 | $1,375 |
| Rosuvastatin Calcium | 58 | $1,196 |
| Gabapentin | 87 | $857 |
| Losartan Potassium | 71 | $817 |
| Pantoprazole Sodium | 60 | $743 |
| Celecoxib | 13 | $697 |
| Diclofenac Sodium | 16 | $559 |
| Lisinopril | 64 | $528 |
| Amitriptyline Hcl | 23 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $318 | $46,27241 claims |
| AstraZenecaFarxiga | $585 | $34,22228 claims |
| MerckJanuvia | $18 | $30,49023 claims |
| Boehringer IngelheimJardiance | $168 | $18,18012 claims |
| AbbVieLinzess | $38 | $10,99813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Ocoee
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.